Some questions on the future of R&D on Covid-19 vaccines. A conversation between Massimo Florio and Giuseppe Remuzzi

Massimo Florio and Giuseppe Remuzzi ()
Additional contact information
Giuseppe Remuzzi: Istituto di Ricerche Farmacologiche Mario Negri IRCCS, https://www.marionegri.it/personale/giuseppe-remuzzi

Working Papers from CSIL Centre for Industrial Studies

Abstract: The paper highlights the need for continued public support for R&D for Covid-19 vaccines. It is structured as a conversation between Professor Giuseppe Remuzzi, scientific director of the 'Mario Negri' Institute for Pharmacological Research, and Professor Massimo Florio, economist principal investigator of the study "Mapping of long-term public and private investment in the development of COVID-19 vaccines", for the European Parliament. Questions dealt with include a) virus mutations and vaccine adaptation, b) Efficacy and duration, c) Clinical effectiveness, d) Safety, and e) target population. The paper is concuded by some social cost-benefit analysis remarks about the creation in the EU of a public infrastructure for R&D and delivery of drugs and vaccines in the public interest

Keywords: Covid-19 Vaccines; Pandemics; R&D and public investment (search for similar items in EconPapers)
JEL-codes: H43 H51 I18 (search for similar items in EconPapers)
Pages: 21 pages
Date: 2024-09-11
New Economics Papers: this item is included in nep-pbe
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.csilmilano.com/docs/WP2024_01.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:mst:wpaper:202401

Access Statistics for this paper

More papers in Working Papers from CSIL Centre for Industrial Studies Contact information at EDIRC.
Bibliographic data for series maintained by Marinella Manghina ().